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Key points  
• The risk of RT-induced breast cancer after Hodgkin lymphoma is strongly associated with a PRS 
for breast cancer in the general population. 
• A PRS, based on nine SNPs interacting with RT in the occurrence of breast cancer after HL, also 
increased RT-induced breast cancer risk. 
 
Abstract  
Female Hodgkin lymphoma (HL) patients treated with chest radiotherapy (RT) have a very high risk of 
breast cancer. The contribution of genetic factors to this risk is unclear. We therefore examined 211,155 
germline single nucleotide polymorphisms (SNPs) for gene-radiation interaction on breast cancer risk in a 
case-only analysis including 327 breast cancer patients after chest RT for HL and 4,671 first primary 
breast cancer patients. Nine SNPs showed statistically significant interaction with RT on breast cancer risk 
(false discovery rate <20%), of which one SNP in the PVT1 oncogene attained the Bonferroni threshold 
for statistical significance. A polygenic risk score (PRS) composed of these SNPs (RT-interaction-PRS) and 
a previously published breast cancer PRS (BC-PRS) derived in the general population were evaluated in a 
case-control analysis comprising the 327 chest-irradiated HL patients with breast cancer and 491 chest-
irradiated HL patients without breast cancer. Patients in the highest tertile of the RT-interaction-PRS had 
a 1.6-fold higher breast cancer risk than those in the lowest tertile. Remarkably, we observed a 4-fold 
increased RT-induced breast cancer risk in the highest compared with the lowest decile of the BC-PRS. 
On a continuous scale, breast cancer risk increased 1.4-fold per standard deviation of the BC-PRS, similar 
to the effect size found in the general population. This study demonstrates that genetic factors influence 
breast cancer risk after chest RT for HL. Given the high absolute breast cancer risk in radiation-exposed 
women, these results can have important implications for the management of current HL survivors and 
future patients. 
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Introduction 
Women who are treated at young ages with chest radiotherapy (RT) for Hodgkin lymphoma (HL) have a 
5-20 times increased risk of breast cancer compared with the general population
1-11
. The cumulative 
incidence of breast cancer up to 40 years after treatment with mantle field RT is 30-40%
5,6,10
, in the 
range of risks observed in BRCA1/2 mutation carriers
12
. The risk of RT-induced breast cancer rises with 
increasing radiation dose and volume, but not all female HL survivors treated with high-dose, high-
volume RT develop breast cancer. Some variation in risk is explained by age at RT exposure, which is 
inversely related with breast cancer risk, and premature menopause induced by concomitant alkylating-
chemotherapy treatment, which reduces risk
13
. However, variation in risk may also be due to genetic 
factors. The high risk of breast cancer in this population provides an excellent opportunity to investigate 
the genetic basis for differential sensitivity to radiation carcinogenesis. Although it is well known that 
ionizing radiation induces DNA damage, the molecular mechanisms underlying radiation-induced breast 
carcinogenesis are unclear. To date, there is no clear evidence that known high-risk breast cancer 
susceptibility genes contribute to RT-induced breast cancer risk in HL patients
14-17
. However, there may 
be a more important role for common susceptibility variants, as suggested by genetic association studies 
in women exposed to low-dose radiation, albeit with conflicting results
18-26
. The role of single nucleotide 
polymorphisms (SNPs) in breast cancer risk after therapeutic high-dose radiation has been investigated in 
few studies: a small genome-wide association study (GWAS) on any second solid malignancy in childhood 
HL survivors
27
 and a GWAS on radiation-induced breast cancer in childhood cancer survivors
28
. In 
addition, Ma et al. investigated 14 SNPs previously associated with breast cancer in the general 
population in HL survivors
29
.  
In the current study, we used a two-step design to investigate whether there are subgroups of women 
exposed to chest RT which are genetically more susceptible to radiation-induced breast cancer. We first 
used a case-only analysis to evaluate interactions between 211,155 SNPs and chest RT, by comparing 
patients with breast cancer after chest RT for HL with first primary breast cancer patients previously 
unexposed to RT. We then conducted a nested breast cancer case-control analysis among chest-
irradiated HL survivors to evaluate a polygenic risk score (PRS) composed of RT-interacting SNPs from 
the case-only analysis (the RT-interaction-PRS). As a separate aim, we studied the effect of a previously 
published PRS for breast cancer in the general population (the BC-PRS)
30
 on breast cancer risk among 
chest-irradiated HL survivors. 
 
Patients and methods 
Study design 
When studying interaction between RT and genetic variation on breast cancer after HL, a classical case-
control study nested in a cohort of HL survivors would not be informative since, until recently, 90% of the 
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patients with breast cancer after HL received RT, resulting in too few unexposed cases. Therefore, we 
used a two-step design to identify susceptibility variants for radiation-induced breast cancer (Figure 1). 
First, we examined gene-radiation interaction for 211,155 SNPs in a case-only analysis comparing 
patients with breast cancer after chest RT for HL (further referred to as breast cancer after HL cases) and 
first primary breast cancer patients (further referred to as first primary breast cancer cases). For each 
SNP, we used logistic regression analysis to estimate the per-allele interaction odds ratio (IOR), a 
measure of departure from a multiplicative joint effect of the SNP and chest RT, for the risk of breast 
cancer, assuming independence between chest RT and the SNP in women from the general population
31
.  
Second, we combined interacting SNPs in a PRS, i.e. the sum of risk alleles weighted by their effect size 
(see Supplementary Methods A for details) and evaluated the association between this PRS and the risk 
of breast cancer after chest RT in a breast cancer case-control analysis among irradiated HL survivors, 
using an independent control group of chest-irradiated HL survivors without breast cancer as controls 
(further referred to as HL controls). We similarly evaluated a second PRS, which was previously reported 
to be associated with breast cancer in the general population (the BC-PRS)
30
.  
 
Study population and genotyping 
For the case-only analysis we pooled 339 cases with breast cancer after HL from three breast cancer 
case-control studies
29,32-34
   nested in HL survivor cohorts: the Childhood Cancer Survivor study (CCSS)
35
, 
a British HL cohort
10
 and the Dutch Hodgkin Lymphoma Cohort
6
. Blood samples from these cases were 
genotyped using a custom Illumina iSelect Array comprising 211,155 SNPs, specially designed for the 
European Collaborative Oncological Gene-Environment Study (EU-COGS) project (referred to as iCOGS 
array)
36
. Extensive patient and HL treatment characteristics, as well as follow-up data were available from 
medical records
4,29,35
, through questionnaires sent to general practitioners and study participants, and 
from record linkages with national cancer registries
6,10,14,29,32-34
. Female patients with breast cancer after 
HL were included in our study if they were diagnosed with primary breast cancer >8 years after chest RT 
for HL before the age of 41 years (see Supplementary Methods B for definition of chest RT). Cases with 
breast cancer after HL were frequency matched (1:~14) on age and year of breast cancer diagnosis (5-
year intervals) and country, to 4,673 first primary breast cancer cases of European origin not known to 
be exposed to chest RT. These were selected from 19,275 participants of 10 studies from the 
Netherlands (NL), United Kingdom (UK), and the United States of America (USA) within the Breast Cancer 
Association Consortium (BCAC)
36
 for whom iCOGS genotype data were available. When there were too 
few subjects in a specific age category, we oversampled in an adjacent age category in the same 
calendar year category.  
For the case-control analysis, we included the 339 cases with breast cancer after HL mentioned 
previously and 508 HL survivors treated with chest RT who did not develop breast cancer until end of 
follow-up, available from the three breast cancer case-control studies described above. For all HL controls 
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without breast cancer, we collected similar data as described above for cases with breast cancer after HL. 
In the published original case-control studies
13,32-34
, which examined radiation dose-response, 1-4 controls 
were individually matched to each case. Controls had to have survived without breast cancer at least as 
long as the interval between HL and breast cancer for the corresponding case, and in case of the US 
study, had to have donated a blood sample. In addition, controls had to match the case on age at HL 
treatment (±3 year) and date of HL treatment (±5 year). Controls from the original case-control studies 
were excluded if they were not treated with chest RT, were treated at or after age 41, and/or did not 
donate a blood sample. In addition, controls were excluded if they developed breast cancer after the year 
of breast cancer diagnosis of the case to whom they had been matched.. For the current study, we added 
recently diagnosed breast cancer after HL cases fulfilling the inclusion criteria. All separate studies 
involved in this collaboration were approved by the relevant Institutional Review Boards, and all 
individuals gave written informed consent.    
 
Quality control on genotype data 
After quality control, 194,106 SNPs measured in 4671 first primary breast cancer cases, 327 cases with 
breast cancer after HL and 491 HL controls without breast cancer remained for analyses. See 
Supplementary Methods C for details on quality control. 
 
Statistical analyses 
In the case-only analysis, comparing breast cancer after HL cases and first primary breast cancer cases, 
we estimated the per-allele IOR by unconditional logistic regression analysis for all variants passing 
quality control, adjusting for the matching factors (age and year of breast cancer diagnosis, both 
continuous, and country) and the first principal component describing remaining genetic ethnic 
differences among European subjects (referred to as ethnicity) (see Supplementary Methods D). P-values 
for the IORs were calculated by the score test performed using the GenABEL package within R (see 
Supplementary Methods E). Based on a conservative Bonferroni correction, SNPs with a P-value <2.6E-07 
were considered statistically significant. Furthermore, we applied the false discovery rate (FDR) by 
Benjamini and Hochberg
37
 to identify SNPs among which the expected proportion of false positives is less 
than 20% (q-value=0.2). For significant SNPs in linkage disequilibrium (LD; r
2
>0.7), only the SNP with 
the lowest P-value was included in the PRS.  
Subsequently, for all subjects in the case-control analysis (breast cancer after HL cases and HL controls) 
we calculated the RT-interaction-PRS consisting of SNPs interacting with RT on breast cancer at 20% FDR 
and the 77-SNP BC-PRS. Missing genotypes were imputed by the mode among HL controls. Odds ratios 
(ORs) and corresponding 95% confidence intervals (CIs) for RT-induced breast cancer after HL were 
calculated by unconditional logistic regression per standard deviation increase in either the RT-
interaction-PRS and/or the BC-PRS, adjusted for each other and for age at HL diagnosis (continuous), 
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year of HL diagnosis (four periods), country, and ethnicity. We also calculated ORs for breast cancer by 
categories of the PRSs (tertiles for the RT-interaction-PRS and deciles for the BC-PRS). P-values for the 
ORs were based on Wald tests. Interaction between the RT-interaction-PRS and gonadotoxic treatment 
for HL (yes/no) and between the RT-interaction-PRS and age at HL treatment (≤20/>20 years) was 
tested by stratification on these factors. As a sensitivity analysis, we assessed the association of a PRS 
including only the SNPs attaining the Bonferroni threshold for statistical significance. For all Bonferroni-
significant SNPs in the case-only analysis, we also tested their individual association with breast cancer 
after chest RT in the case-control analysis using logistic regression adjusted for age at and year of HL 
diagnosis, country, and ethnicity. All analyses were conducted with R software (http://www.r-
project.org).  
 
Data availability 
Non-identifiable data that support the findings of this study will be made available upon reasonable 
request. Access to the BCAC data is governed by the Data Access Coordinating Committee from BCAC. 
Data from the CCSS study can be retrieved from dbGAP using accession number phs001327.v1.p1.  
 
Results 
Study populations of the case-only and case-control analysis 
We included 327 breast cancer after HL cases from cohorts of female HL patients in NL, UK, and USA and 
4,671 frequency-matched first primary breast cancer cases previously unexposed to RT from the same 
countries in the case-only analysis. Further, we included 491 HL controls in the case-control analysis (see 
Table 1 for the numbers of subjects by country). The median age at breast cancer diagnosis was 45 
years (range 24-76) for breast cancer after HL cases and 46 years (range 22-84) for age-matched first 
primary breast cancer cases (Table 1). The median interval between HL and breast cancer diagnosis was 
24 years (range 9-46). For HL controls median follow-up was 30 years (range 9-49). Most HL cases and 
controls (87%) were treated with mantle field irradiation, whereas 11% of the HL cases and controls 
received mediastinal radiotherapy without axillary node radiotherapy. About half of the breast cancer 
after HL cases and almost 60% of HL controls were treated for HL with chemotherapy in addition to RT. 
About 45% of breast cancer after HL cases and 57% of HL controls received gonadotoxic treatment (i.e., 
alkylating chemotherapy and/or pelvic RT).       
 
SNPs interacting with RT on breast cancer risk (case-only analysis) 
We tested 194,106 SNPs that passed quality control for an interaction with chest RT in the case-only 
analysis of breast cancer patients (QQ plot is depicted in Supplementary Figure 1). As shown in Table 2, 
three SNPs were statistically significantly associated at the Bonferroni threshold for multiple testing (P 
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<2.6E-07) and seven additional SNPs met the 20% FDR threshold, of which one SNP was excluded 
because of strong LD (r
2
 0.9). The estimated per-allele IORs for these nine SNPs ranged from 1.6 to 2.2. 
Most SNPs were quite common in the breast cancer after HL cases with minor allele frequencies (MAF) 
between 2.8% and 43.7%.  
 
 
Polygenic risk score for RT-induced breast cancer (case-control analysis) 
We constructed a RT-interaction-PRS of the nine SNPs that showed a statistically significant (FDR 20%) 
interaction with RT-induced breast cancer. The RT-interaction-PRS increased breast cancer risk after 
chest RT for HL with ORs of 1.2 (95% CI, 0.8-1.7; P=0.348) and 1.6 (95% CI, 1.1-2.4; P=0.007), 
respectively, for the middle and highest tertiles compared with the lowest tertile, adjusted for age and 
year of HL diagnosis, country, ethnicity, and the BC-PRS (Figure 2 and Supplementary Table 1). The OR 
per one standard deviation (SD) of the RT-interaction-PRS was 1.3 (95% CI, 1.1-1.5; P=0.002). 
Additional adjustment for gonadotoxic treatment did not affect the association of the RT-interaction-PRS 
with breast cancer risk (OR
adjusted
 1.3, 95% CI 1.1-1.5), suggesting that it unlikely that chemotherapy has 
confounded our analyses. In addition, stratified analyses resulted in similar associations between the RT-
interaction-PRS and breast cancer risk among women who received gonadotoxic treatment (alkylating 
chemotherapy and/or pelvic RT) and women who did not; we observed no statistically significant 
interaction between the RT-interaction-PRS and gonadotoxic treatment (P=0.337; Supplementary Table 
1). Likewise, stratification by age at HL treatment (≤20, >20 years) did not result in different associations 
between the RT-interaction-PRS and breast cancer risk after RT for HL; there was no interaction between 
age at HL treatment and the RT-interaction PRS (P=0.954).  
In a sensitivity analysis, we observed that a PRS containing only the three SNPs reaching the Bonferroni 
threshold for statistical significance also increased breast cancer risk with ORs of 1.4 (95% CI, 1.0-2.1; 
P=0.070) and 1.6 (95% CI, 1.1-2.2; P=0.018), respectively, for the middle and highest tertile compared 
with the lowest tertile which consisted of non-carriers. The OR per one SD of the 3-SNP RT-interaction-
PRS was 1.2 (95% CI, 1.0-1.4; P=0.014).  
 
In order to confirm the observed associations, we also evaluated the individual effects of the three 
Bonferroni-significant SNPs on RT-induced breast cancer in the case-control analysis among chest-
irradiated HL survivors (Supplementary Table 2). Of these, an intronic variant in oncogene PVT1 
(rs10505506) was associated with RT-induced breast cancer risk after HL with an OR of 1.3 (95% CI 1.1-
1.6; P=0.007) per allele copy. Of note, rs10505506 is not in LD (r
2
 <0.3 in Europeans from the 1000 
Genomes Project
38
) with previously identified cancer risk variants in the PVT1 locus (Supplementary 
Figure 2).   
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Polygenic risk score based on known breast cancer SNPs (case-control analysis) 
To evaluate the combined effect of known breast cancer SNPs, we studied a BC-PRS containing 76 SNPs 
which increase breast cancer risk in the general population
30
, in chest-irradiated HL survivors. The BC-
PRS was associated with a 1.4-fold increased risk of RT-induced breast cancer (95% CI, 1.2-1.6; P=9.1E-
05) per standard deviation increase in the BC-PRS. The ORs for developing breast cancer after chest RT 
for HL by deciles of the BC-PRS, compared with women in the middle quintile (40
th
 to 60
th
 percentile), are 
shown in Figure 3 and Supplementary Table 3. The 10% of women with the lowest BC-PRS had an OR of 
0.6 (95% CI, 0.3-1.1; P=0.133) for developing RT-induced breast cancer compared with women in the 
middle quintile, whereas the OR for the 10% of women with the highest BC-PRS was 2.4 (95% CI, 1.4-
4.2; P=0.002), adjusted for age and year of HL diagnosis, country, ethnicity, and the RT-interaction-PRS 
(in tertiles). This results in a 4-fold relative risk for the 10% women with the highest compared with the 
lowest BC-PRS. There was no interaction between the RT-interaction-PRS and the BC-PRS (P=0.645). 
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Discussion   
This study demonstrates that genetic factors influence the risk of breast cancer after chest RT for HL. We 
showed that a BC-PRS, consisting of 77 SNPs previously associated with breast cancer in the general 
population, also substantially increases the risk of breast cancer in chest-irradiated HL survivors. In 
addition, we identified nine SNPs interacting with chest RT and the risk of breast cancer after HL and we 
showed a statistically significant association of a PRS composed of these interaction SNPs with breast 
cancer risk after chest RT for HL using an independent control group. These results imply that the 
absolute risk of breast cancer due to irradiation would be (even) larger among women at high genetic 
risk, which is relevant for clinical risk prediction. 
Importantly, we validated the previously published BC-PRS in a high-risk population of female chest-
irradiated HL survivors and found that there are large differences in risk between women with a low and 
high PRS. More specifically, we observed a 4-fold increased relative risk between chest-irradiated HL 
survivors in the highest compared with the lowest decile of the BC-PRS. On a continuous scale, the effect 
size was very similar to that found in the general population (OR of 1.4 per SD in our study of HL 
survivors compared with ORs of 1.4 to 1.6 per SD in the general population)
30,39
. These results indicate 
that the effects of radiation exposure and common susceptibility variants, summarized in the PRS, 
combine approximately multiplicatively. Given the high absolute breast cancer risk in radiation-exposed 
women, these results have important implications for their management. The BC-PRS can be used to help 
guide treatment decisions in newly diagnosed HL patients as well as to help determine breast surveillance 
strategies for irradiated HL survivors. Annual breast cancer surveillance between the ages of 25 and 50 
years is currently recommended by the International Late Effects of Childhood Cancer Guideline 
Harmonization Group for female survivors of childhood, adolescent, and young adult cancer who received 
≥20 Gy chest radiation before age 30 years
40
. Less clear is the evidence for surveillance in women 
treated at older ages, with lower dosages, or with different radiation volumes. Therefore, clinical 
prediction models for breast cancer that include both clinical and genetic factors can help to identify 
(additional) women who may benefit from breast cancer surveillance.     
We chose to evaluate the 77-SNP BC-PRS by Mavaddat et al.
30
, as this PRS has been associated with 
breast cancer risk in the general population and in high-risk groups such as BRCA1 and BRCA2 mutation 
carriers
39,41
, allowing direct comparison of the reported effect sizes. Nevertheless, many more common 
susceptibility variants have recently been identified for breast cancer in the general population
42,43
. 
Addition of these SNPs to the BC-PRS may further improve risk stratification for breast cancer in chest-
irradiated HL survivors and in other high-risk groups. Inclusion of SNPs associated with hormone 
receptor-negative breast cancer may be of particular interest, as several studies have reported that HL 
survivors are more likely to develop hormone receptor-negative disease
44-46
.  
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We applied an innovative design to examine the role of SNP-radiation interactions in breast cancer risk 
after HL. This is not feasible in a classical breast cancer case-control study in HL survivors, as, until 
recently, approximately 90% of breast cancer cases after HL received chest RT. Therefore, we first 
performed a case-only analysis in breast cancer patients previously exposed and unexposed to chest RT, 
followed by a case-control analysis in HL survivors to evaluate the combined effect of the identified RT-
interaction SNPs in a PRS. We used a 20% FDR as a cut-off to select SNPs interacting with RT for the RT-
Interaction-PRS, as it has been shown that the performance of a PRS improves when using more liberal 
thresholds than the conservative Bonferroni threshold
47,48
. Although a PRS consisting of three SNPs 
statistically significant at the Bonferroni threshold showed a similar association with RT-induced breast 
cancer risk among HL survivors, the goodness-of-fit was better in the full PRS (data not shown).    
The IORs which we estimated in the case-only analysis measure departure from a multiplicative joint 
effect of chest RT and the SNP, assuming independence between chest RT and the SNP in women from 
the general population
49
. This assumption is likely to be justified except for SNPs associated with HL. 
SNPs associated with HL may also have shown a significant IOR in the case-only analysis. On the other 
hand, such SNPs may be associated with both HL and (radiation-induced) breast cancer and, therefore, 
we did not exclude SNPs previously associated with HL from inclusion in the RT-Interaction-PRS. If they 
were only associated with HL they would have attenuated the association of the RT-Interaction-PRS with 
breast cancer after chest-RT in the case-control analysis. In the case-only analysis, we identified one SNP 
(rs9461776) interacting with radiation at 20% FDR significance located in the human leukocyte antigen 
(HLA) region, which has extensively been reported to be associated with HL
50
. rs9461776 showed no 
evidence of an association with breast cancer after chest RT (OR 1.0; 95%CI, 0.8-1.4; P>0.5) in the 
case-control analysis in HL survivors and may therefore have attenuated the association of the RT-
Interaction-PRS with the risk of breast cancer after chest RT.   
Of the nine SNPs (MAF>1%) interacting with RT on breast cancer risk at 20% FDR, one attained the 
genome-wide level (P<5x10-8) of statistical significance. This SNP (rs10505506) was also associated with 
breast cancer risk in chest-irradiated HL survivors (OR 1.3; 95%CI, 1.1-1.6; P=0.007). SNP rs10505506 is 
located in the intronic region of PVT1, which is a known oncogene regulated by tumor suppressor p53 
encoding a long non-coding RNA and several microRNAs
51,52
. PVT1 has been shown to interact with the 
adjacent proto-oncogene MYC and translocations in this locus have been associated with Burkitt's 
lymphoma. In addition, overexpression of PVT1 is associated with several types of cancers including 
breast cancer, acute myeloid leukemia and HL. Likewise, GWAS studies have identified several 
conditionally independent SNPs in this locus associated with cancer, including breast cancer and HL
53,54
, 
but none of these are in LD with rs10505506. A potential link with radiation has recently been suggested 
in a mouse model after whole-body irradiation
55
.     
The association of the RT-interaction-PRS with breast cancer risk after HL was not weakened in ‘low-risk’ 
groups of women irradiated at older age (i.e. 20 years or older) or women treated with gonadotoxic 
For personal use only.on January 14, 2019. by guest  www.bloodjournal.orgFrom 
12 
 
treatment. In addition, we did not observe interaction between the RT-interaction-PRS and either 
gonadotoxic treatment or age at HL treatment. This is in line with the notion that gonadotoxic treatment 
and age at HL treatment are independent risk factors for breast cancer risk after HL. This suggests that 
age and treatment-related risk factors for breast cancer after HL and the genetic risk scores (both the 
RT-interaction-PRS and the BC-PRS) combine multiplicatively as has previously been shown for several 
reproductive risk factors and the 77-SNP BC-PRS in the general population
56
. 
A limitation of this study is that the study populations for the construction and evaluation of the RT-
interaction-PRS were not independent, as the breast cancer after HL cases were included in both 
analyses. External validation of the RT-interaction-PRS in an independent study is therefore needed to 
confirm our findings. In addition, we excluded SNPs with a low MAF (<1%) from our analyses, as these 
low-frequency SNPs are more prone to genotyping errors. However, Morton et al., recently reported two 
suggestive associations for low-frequency variants at 11q23 and 1q32.3, both not present on the iCOGs 
array, with breast cancer risk after childhood cancer
28
, suggesting a potential role for low-frequency SNPs 
in RT-induced breast cancer. Inclusion of these SNPs to the RT-interaction-PRS might strengthen its 
association with RT-induced breast cancer. Likewise, additional SNPs interacting with RT on breast cancer 
may be identified when assessing SNP data from denser genotyping chips imputed to a reference panel. 
However, in this first analysis, we focused on high-quality SNPs specifically selected for the iCOGs array.  
In conclusion, we showed that a BC-PRS previously developed in the general population also applies in a 
high-risk breast cancer population of chest irradiated HL survivors. In addition, we developed a RT-
interaction-PRS composed of nine SNPs interacting with radiation that was associated with raised breast 
cancer risk after chest RT for HL. While our RT-interaction-PRS needs validation in an independent 
sample, the BC-PRS can already be applied in clinical practice. This can benefit treatment-decision 
making in future HL patients as well as identification of high-risk survivors eligible for breast cancer 
surveillance.    
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Table 1. Population characteristics of the breast cancer after Hodgkin lymphoma cases, first 
primary breast cancer cases and Hodgkin lymphoma controls without breast cancer. 
 Breast cancer 
after Hodgkin 
lymphoma cases 
(N=327) 
First primary breast 
cancer cases 
 
(N=4,671) 
Hodgkin lymphoma 
controls without 
breast cancer 
(N=491) 
                
N  % 
               
N  % 
                 
N   % 
Age at breast cancer 
diagnosis, y 
Median (range) 
 
 
45 (24-76) 
 
 
46 (22-84) 
 
 
NA 
 
20-29 8 2.4 96 2.1 NA  
30-39 88 26.9 855 18.3 NA  
40-49 139 42.5 2,224 47.6 NA  
50-59 68 20.8 1,129 24.2 NA  
60-69 20 6.1 314 6.7 NA  
70+ 4 1.2 53 1.1 NA  
Year of breast cancer 
diagnosis*  
   
 
   
Median (range) 2003 (1984-2013) 2000 (1964-2011) NA  
<1990 12 3.7 226 4.8 NA  
1990-1994 25 7.6 606 13.0 NA  
1995-1999 72 22.0 1,377 29.5 NA  
2000-2004 86 26.3 1,329 28.5 NA  
2005-2009 99 30.3 1,067 22.8 NA  
2010-2014 33 10.1 66 1.4 NA  
Age at Hodgkin lymphoma 
diagnosis, y 
Median (range) 
 
 
19 (10-40) 
 
 
NA 
  
 
22 (6-40) 
<15 40 12.2 NA  36 7.3 
15-19 134 41.0 NA  140 28.5 
20-24 76 23.2 NA  140 28.5 
25-29 38 11.6 NA  76 15.5 
30-34 31 9.5 NA  85 17.3 
35-40 8 2.4 NA  14 2.9 
Year of Hodgkin lymphoma 
diagnosis† 
      
1965-1973 92 28.1 NA  119 24.2 
1974-1979 120 36.7 NA  132 26.9 
1980-1984 60 18.3 NA  109 22.2 
1985-1999 55 16.8 NA  131 26.7 
Interval between Hodgkin 
lymphoma and breast 
cancer diagnosis (cases)  
or end of follow-up 
(controls), y 
Median (range) 
 
 
 
 
 
 
24 (9-46) 
 
 
 
 
 
 
NA 
  
 
 
 
 
 
30 (9-49) 
9-<15 28 8.6 NA  6 1.2 
≥15-<25 144 44.0 NA  113 23.0 
≥25-<35 127 38.8 NA  238 48.5 
≥35 28 8.6 NA  134 27.3 
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Hodgkin lymphoma 
treatment‡ 
      
Radiotherapy only 160 48.9 NA  201 40.9 
Radiotherapy and 
chemotherapy 160 48.9 
 
NA 
 
284 57.8 
Radiotherapy; 
chemotherapy missing 7 2.1 
 
NA 
 
6 1.2 
Mantle field irradiation§       
     Yes 234 90.7 NA  371 84.9 
     No 18 7.0 NA  60 13.7 
     Missing 6 2.3 NA  6 1.4 
Pelvic radiotherapy
||
       
Yes 39 11.9 NA  59 12.0 
No 288 88.1 NA  432 88.0 
Alkylating chemotherapy
¶
 
      
    Yes 133 40.7 NA  253 51.5 
    No 176 53.8 NA  211 43.0 
    Missing 18 5.5 NA  27 5.5 
Gonadotoxic treatment       
Alkylating chemotherapy 
and/or pelvic radiotherapy 
152 46.5 NA  278 56.6 
No alkylating 
chemotherapy and no 
pelvic radiotherapy 
158 48.3 NA  192 39.1 
Missing 17 5.2 NA  21 4.3 
Country       
The Netherlands 112  34.3 1,646 35.2 168 34.2 
United Kingdom 146 44.6 2,380 51.0 269 54.8 
United States of America 69 21.1 645 13.8 54 11.0 
IQR indicates interquartile range 
 
* Four cases with breast cancer after Hodgkin lymphoma had missing year of breast cancer diagnosis, which were imputed with the 
median year of breast cancer diagnosis among participants from the same country. 
† Four cases with breast cancer after Hodgkin lymphoma and six Hodgkin lymphoma controls had missing year of Hodgkin 
lymphoma diagnosis. These missing years were imputed with the median year of Hodgkin lymphoma diagnosis among participants 
in the same group (cases or controls) from the same country. 
‡ For the Dutch Hodgkin lymphoma survivors, chest RT was defined as (in)complete mantle field or mediastinal RT, or RT to the 
lungs or axilla. Subjects with only infradiaphragmatic RT were excluded. 
For Hodgkin lymphoma survivors from the USA, chest RT was defined as chest or total nodal RT (subjects with only brain, other 
head, neck, abdomen, spine, pelvis and/or limb RT were excluded). 
For Hodgkin lymphoma survivors from the UK, chest RT was defined as mantle field, chest, mediastinal, axillary, mini mantle field or 
partial chest RT (subjects with only neck, clavicular and/or head or other supradiaphragmatic RT or infradiaphragmatic RT,  RT field 
unknown or chemotherapy only were excluded). 
§ Information on the radiation fields was only available for HL survivors from the UK and The Netherlands. 
|| Pelvic RT encompassed RT to the whole abdomen or iliac nodes on both sides, or RT with inverted Y field, in women with no 
(successful) oophoropexy. 
¶ Alkylating chemotherapy consists of combinations of cytostatic agents with at least one alkylating agent (i.e. procarbazine, 
cyclophosphamide, ifosfamide, lomustine, melphalan, dacarbazine, cisplatin, mechlorethamine, chlorambucil, and carmustine). 
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Table 2. Characteristics of SNPs statistically significantly (20% FDR) interacting with RT in the case-only analysis 
     
Breast cancer 
after Hodgkin 
lymphoma cases   
(N=327) 
First primary breast 
cancer cases       
(N=4671) 
Statistical interaction with 
chest-RT on breast cancer risk* 
Weight RT-
interaction-PRS 
SNP Locus Chr Position† Alleles MAF N called MAF N called IOR 
95% CI 
P ‡ Log IOR 
rs10505506 PVT1 8 129114473 G/C 0.407 327 0.306 4670 1.6 
1.3 - 1.8 
3.1E-08 0.44 
rs12086369 1p31.1 1 79644149 G/A 0.073 324 0.035 4667 2.1 1.5 - 2.8 9.4E-08 0.74 
rs9461776 HLA 6 32683713 A/G 0.133 327 0.079 4671 1.8 
1.4 - 2.3 
1.1E-07 0.59 
MitoA7769G MT 7769 A/G 0.052 325 0.020 4653 2.1 
1.5 - 3.0 
2.8E-06 0.76 
rs1017639 CPT1A 11 68355110 A/C 0.073 327 0.043 4669 1.9 1.4 - 2.6 2.8E-06 0.63 
MitoT9900C MT 9900 A/G 0.028 325 0.011 4669 2.0 
1.3 - 3.2 
3.7E-06 0.71 
MitoA13781G MT 13781 A/G 0.036 306 0.011 4592 2.2 
1.5 - 3.3 
4.3E-06 0.80 
rs2296008 COL19A1 6 70935424 G/A 0.041 327 0.020 4669 2.2 1.4 - 3.4 6.8E-06 0.79 
rs3815871 PVT1 8 129077760 G/C 0.437 327 0.341 4671 1.5 
1.3 - 1.8 
8.5E-06 0.40 
Chr indicates chromosome; CI, confidence interval; FDR, false discovery rate; IOR, interaction odds ratio; MAF, minor allele frequency; MT, mitochondrial DNA; PRS, polygenic risk 
score; RT, radiotherapy ; and SNP, single nucleotide polymorphism  
 
* Logistic regression analysis per SNP to test the log additive effect per allele (per-allele IOR) with adjustment for age at and year of breast cancer diagnosis, country, and ethnicity. 
† Positions are based on NCBI36/hg18.  
‡ All listed SNPs were significant at a 20% FDR. Top three SNPs were statistically significant at the Bonferroni threshold (P <2.6E-07). 
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Figure 1. Study design 
 
Figure 2. Risk of breast cancer after chest RT by tertiles of the RT-interaction-PRS among HL survivors 
 
Figure 3. Risk of breast cancer after chest RT by deciles of the BC-PRS in the breast cancer after Hodgkin lymphoma case-control 
analysis 
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